Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.00111358574610243 0.0367483296213809 0.0801781737193765 0.0879732739420936
Stock impact report

ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [Seeking Alpha]

ARS Pharmaceuticals, Inc. (SPRY) 
Company Research Source: Seeking Alpha
As of September 30, 2025, ARS Pharma had cash, cash equivalents, and short-term investments of $288.2 million, with 98,844,178 shares of common stock outstanding. More on ARS Pharmaceuticals ARS Pharmaceuticals: A Significant Upside Is Expected From neffy ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript ARS Pharmaceuticals Q3 2025 Earnings Preview ARS Pharma secures $250M loan to accelerate Neffy rollout Seeking Alpha's Quant Rating on ARS Pharmaceuticals Show less Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for SPRY alerts
Opt-in for
SPRY alerts

from News Quantified
Opt-in for
SPRY alerts

from News Quantified